Blog
RSS FeedPosted by Michael Wonder on 20 Mar 2020
Decision to decline inactive medicines funding applications
20 March 2020 - To give people more clarity about what medicines PHARMAC is, or is not, actively considering for ...
Posted by Michael Wonder on 12 Mar 2020
PHARMAC funds new medicine (mepolizumab) for severe asthma
12 March 2020 - Around 500 New Zealanders who have severe asthma will have access to a new medicine, mepolizumab, ...
Posted by Michael Wonder on 10 Mar 2020
Decision to fund betamethasone dipropionate with calcipotriol (Enstilar) foam spray for psoriasis
10 March 2020 - PHARMAC is pleased to announce the approval of a decision to fund a new topical psoriasis ...
Posted by Michael Wonder on 26 Feb 2020
Vertex announces availability of cystic fibrosis medicine Kalydeco (ivacaftor) in New Zealand
25 February 2020 - Vertex Pharmaceuticals today announced that Kalydeco (ivacaftor) will be available to eligible patients with cystic fibrosis ...
Posted by Michael Wonder on 26 Feb 2020
Decision to fund ivacaftor (Kalydeco) for people with cystic fibrosis with the G551D mutation
26 February 2020 - PHARMAC is pleased to announce a decision to fund ivacaftor (Kalydeco) for the treatment of people ...
Posted by Michael Wonder on 20 Feb 2020
Outcomes from the November 2019 PTAC meeting
20 February 2020 - PHARMAC has published a record of the November 2019 Pharmacology and Therapeutics Advisory Committee meeting. ...
Posted by Michael Wonder on 12 Feb 2020
Decision for funding in the blood, alimentary and immunosuppressant therapy areas
12 February 2020 - PHARMAC is pleased to announce a decision to approve proposals relating to medicines in the blood, ...
Posted by Michael Wonder on 12 Dec 2019
Decision to award sole supply for fluticasone and fluticasone with salmeterol metered dose inhalers
12 December 2019 - PHARMAC has made a decision to make changes to the funded brands of fluticasone and fluticasone ...
Posted by Michael Wonder on 11 Dec 2019
Decision to award sole supply for apomorphine hydrochloride
11 December 2019 - PHARMAC are pleased to announce changes to the funding of apomorphine hydrochloride, a medicine used to ...
Posted by Michael Wonder on 05 Dec 2019
Decision to fund two new cancer treatments: olaparib and fulvestrant
5 December 2019 - PHARMAC is pleased to announce a decision to fund two new cancer treatments and amend the ...
Posted by Michael Wonder on 05 Nov 2019
PHARMAC funding new leukaemia medicine
4 November 2019 - New Zealanders with chronic lymphocytic leukaemia will have another medicine option available to help them live ...
Posted by Michael Wonder on 07 Oct 2019
'Left on the scrapheap': PHARMAC decision bittersweet for MS patients
7 October 2019 - A Motueka grandmother says the national drug-buying agency is abandoning her on the scrapheap with "inhumane" ...
Posted by Michael Wonder on 07 Oct 2019
PHARMAC signs bundle deal for more cancer medicines
7 October 2019 - 420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each ...
Posted by Michael Wonder on 11 Sep 2019
Decision for funding in the immunosuppressant, cardiovascular and anti-nausea therapeutic areas
11 September 2019 - PHARMAC pleased to announce a decision to approve proposals relating to medicines in the immunosuppressant, cardiovascular ...
Posted by Michael Wonder on 22 Aug 2019
PTAC continues to find new ways to reject new medicines (Part 2)
23 August 2019 - More startling insights from the minutes of the May 2019 PTAC meeting. ...